1. Pink Sheet

Enhertu Nabs A First With UK Standalone Approval

Advanced Breast Cancer Treatment Is First New Cancer Drug Approved In 2021

 
• By Vibha Sharma

The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.

Realistic pink ribbon, breast cancer awareness symbol, vector illustration
There is significant unmet clinical need for patients with HER2 positive metastatic breast cancer • Source: Shutterstock

Daiichi Sankyo/AstraZeneca’s Enhertu (trastuzumab deruxtecan) has become the first new cancer medicine to be authorized by the UK’s Medicines and Healthcare products Regulatory Agency since it became an independent regulator in January following the end of the Brexit transition period.

Enhertu has been granted conditional authorization in the UK as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 
• By Sarah Karlin-Smith

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By Kate Rawson

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.